Home

Verona Pharma plc - American Depositary Shares (VRNA)

84.34
-1.20 (-1.40%)
NASDAQ · Last Trade: Jun 8th, 8:34 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close85.54
Open85.79
Bid83.62
Ask84.34
Day's Range82.18 - 86.26
52 Week Range11.79 - 86.59
Volume1,740,317
Market Cap40.51B
PE Ratio (TTM)-337.36
EPS (TTM)-0.3
Dividend & YieldN/A (N/A)
1 Month Average Volume1,433,199

Chart

About Verona Pharma plc - American Depositary Shares (VRNA)

Verona Pharma is a biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company concentrates on the discovery and development of impactful drugs that address significant unmet medical needs in conditions such as chronic obstructive pulmonary disease (COPD) and asthma. Their research and pipeline involve novel mechanisms of action, aiming to improve patient outcomes and quality of life through enhanced treatment options. Verona Pharma utilizes its expertise in drug development to advance potential therapies from preclinical stages through clinical trials. Read More

News & Press Releases

Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Todayfool.com
Via The Motley Fool · June 5, 2025
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Databenzinga.com
Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not meet its main goal.
Via Benzinga · May 30, 2025
Jim Cramer Says This Quantum Computing Stock Is 'So High' And 'Too Speculative'benzinga.com
Via Benzinga · May 28, 2025
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · May 27, 2025
Earnings Scheduled For April 29, 2025benzinga.com
Via Benzinga · April 29, 2025
Earnings Scheduled For February 27, 2025benzinga.com
Via Benzinga · February 27, 2025
Earnings Scheduled For February 29, 2024benzinga.com
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via Benzinga · February 29, 2024
Earnings Preview For Verona Pharmabenzinga.com
Via Benzinga · February 28, 2024
10 Health Care Stocks With Whale Alerts In Today's Sessionbenzinga.com
Via Benzinga · April 1, 2025
Why Verona Pharma, A Triple-Digit Gainer In 2024, Surged Another 22% This Weekinvestors.com
The company is working to launch its COPD treatment more broadly. The drug is a non-steroidal nebulizer.
Via Investor's Business Daily · January 16, 2025
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixentinvestors.com
The FDA signed off on Regeneron and Sanofi's Dupixent for patients with uncontrolled COPD.
Via Investor's Business Daily · September 27, 2024
Petco, AppLovin, Dave & Buster's And Other Big Stocks Moving Higher On Wednesdaybenzinga.com
Via Benzinga · September 11, 2024
GSK's Asthma Drug Meets Main Goal In Phase 3 Study In Patients With Smoker's Lungs, Prepares Competition With Amgen/AstraZeneca's Drugbenzinga.com
GSK's Phase 3 MATINEE trial of Nucala in COPD met the primary endpoint, reducing exacerbations significantly over 104 weeks.
Via Benzinga · September 6, 2024
Top 3 Health Care Stocks That May Crash In Augustbenzinga.com
Via Benzinga · August 14, 2024
9 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · August 13, 2024
VRNA Stock Earnings: Verona Pharma Misses EPS for Q2 2024investorplace.com
VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 8, 2024
Top 3 Health Care Stocks You May Want To Dump This Quarterbenzinga.com
Via Benzinga · July 30, 2024
First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Productbenzinga.com
The FDA has approved Verona Pharma's Ohtuvayre (ensifentrine) as maintenance treatment of chronic obstructive pulmonary disease in adults. The drug could generate $3.6 billion in peak sales.
Via Benzinga · June 27, 2024
10 Health Care Stocks Whale Activity In Today's Sessionbenzinga.com
Via Benzinga · June 25, 2024
5 Biotech Stocks With Key Catalysts This Week: Merck, Intellia, Verona, And Morebenzinga.com
Biotech investing is risk-fraught but the returns could be staggering if one chooses to take the educated approach.
Via Benzinga · June 24, 2024
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursdaybenzinga.com
Via Benzinga · June 13, 2024
Why It's A New Day For COPD Patients — And Regeneron, Sanofi, Verona Stocksinvestors.com
The companies are closing in on the finish line for two new COPD treatments.
Via Investor's Business Daily · June 13, 2024
VRNA Stock Earnings: Verona Pharma Misses EPS for Q1 2024investorplace.com
VRNA stock results show that Verona Pharma missed analyst estimates for earnings per share the first quarter of 2024.
Via InvestorPlace · May 9, 2024
3 Healthcare Stocks That Have Outperformed Nvidia Since 2022fool.com
The healthcare sector is no slouch when it comes to top-performing growth stocks.
Via The Motley Fool · March 1, 2024
3 Stocks That Could Be Monster Winners in 2024fool.com
Don't be surprised if these three stocks take off in the new year.
Via The Motley Fool · December 30, 2023